Keywords: neopharm, regains, oncology, products, says, regained, rights
NeoPharm regains oncology products
Article | 27 September 2004
NeoPharm says that it has regained the rights for liposome-encapsulated paclitaxel and liposome-encapsulated doxorubicin from pharmaceutical giant Pfizer.
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
